What is the MOA of EGFR inhibitor (Cetuximab, Panitumumab)?
Binds to EGFR and competitively inhibits the binding of EGF which prevents phosphorylation and activation of receptor kinases thereby inhibiting cell growth, metastasis and signal transduction
What is EGFR? Which mutation can it result?
Epidermal growth factor
Can result in K-ras wild type mutation
Which drug can have dermatologic toxicity side effect and magnesium wasting?
EGFR inhibitors (Cetuximab, Panitumumab)
Which drug can lead to infusion reactions and cardiopulmonary arrest?
Cetuximab (an EGFR inhibitor)
Skin rash/lesion as a side effect is associated with ____-
EGFR inhibitors (Cetuximab, Panitumumab)
True/false: VEGF inhibitor can cause HTN and that can be managed with the usual antihypertensives
True
What are agents of tyrosine kinase inhibitors:
Erlotinib
Regorafenib
What is the MOA of TKI?
Prohibit phosphorylation of intracellular tyrosine kinase residue by blocking ATP binding sites
Erlotinib is the tyrosine kinase inhibitor of _______
EGFR
Major toxicities of Erlotinib:
Interstitial lung disease
Renal failure
Hepatotoxicity
GI perforation
Hemolytic anemia
True/false: Regorafenib is metabolized by CYP3A4 and should be used separately from antacid and PPIs
False; that’s for erlotinib
Which TKI affects angiogenesis/ VEGF? EGFR?
Regorafenib- VEGF
Erlotinib- EGFR
Which TKI can cause hand-foot syndrome?
Regorafenib
What are common side effects of erlotinib?
Rash and diarrhea
Erlotinib should be taken with/on _________. Regorafenib should be taken with/on_______